{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T07:14:29Z","timestamp":1771658069177,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1007\/s00105-006-1240-6","type":"journal-article","created":{"date-parts":[[2006,10,11]],"date-time":"2006-10-11T17:54:23Z","timestamp":1160589263000},"page":"969-974","source":"Crossref","is-referenced-by-count":3,"title":["Arzneimittelnebenwirkungen bei antiretroviraler Therapie","The side effects of antiretroviral therapy"],"prefix":"10.1007","volume":"57","author":[{"given":"M.","family":"Hartmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1240_CR1","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0190-9622(03)02099-1","volume":"49","author":"Ball","year":"2003","unstructured":"Ball RA, Kinchelow T (2003) Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. J Am Acad Dermatol 49: 826\u2013831","journal-title":"J Am Acad Dermatol"},{"key":"1240_CR2","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1097\/00002030-200009290-00012","volume":"14","author":"Barreiro","year":"2000","unstructured":"Barreiro P, Soriano V, Casas et al. (2000) Prevention of nevirapine-associated exanthema using slow dose escalation and\/or corticosteroids. AIDS 14: 2153\u20132157","journal-title":"AIDS"},{"key":"1240_CR3","doi-asserted-by":"crossref","first-page":"F63","DOI":"10.1097\/00002030-199907090-00001","volume":"13","author":"Behrens","year":"1999","unstructured":"Behrens G, Dejam A, Schmidt H et al. (1999) Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: F63\u2013F70","journal-title":"AIDS"},{"key":"1240_CR4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","volume":"46","author":"Birkus","year":"2002","unstructured":"Birkus G, Hitchcock MJ, Cihlar T (2002) Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46: 716\u2013723","journal-title":"Antimicrob Agents Chemother"},{"key":"1240_CR5","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","volume":"356","author":"Carr","year":"2000","unstructured":"Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356: 1423\u20131430","journal-title":"Lancet"},{"key":"1240_CR6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","volume":"361","author":"Carr","year":"2003","unstructured":"Carr A, Emery S, Law M et al. (2003) An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361: 726\u2013735","journal-title":"Lancet"},{"key":"1240_CR7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1529-8027.2001.006001014.x","volume":"6","author":"Dalakas","year":"2001","unstructured":"Dalakas MC (2001) Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst 6: 14\u201320","journal-title":"J Peripher Nerv Syst"},{"key":"1240_CR8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1086\/378131","volume":"37","author":"Dube","year":"2003","unstructured":"Dube MP, Stein JH, Aberg JA et al. (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 37: 613\u2013627","journal-title":"Clin Infect Dis"},{"key":"1240_CR9","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","volume":"15","author":"Fagot","year":"2001","unstructured":"Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN et al. (2001) Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 15: 1843\u20131848","journal-title":"AIDS"},{"key":"1240_CR10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/00002030-200305230-00010","volume":"17","author":"Friis-Moller","year":"2003","unstructured":"Friis-Moller N, Weber R, Reiss P et al. (2003) Cardiovascular disease risk factors in HIV patients \u2013 association with antiretroviral therapy. Results from the DAD study. AIDS 17: 1179\u20131193","journal-title":"AIDS"},{"key":"1240_CR11","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJM199709113371102","volume":"337","author":"Gulick","year":"1997","unstructured":"Gulick RM, Mellors JW, Havlir D et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734\u2013739","journal-title":"N Engl J Med"},{"key":"1240_CR12","first-page":"159","volume":"51","author":"Hartmann","year":"2000","unstructured":"Hartmann M, Petzoldt D (2000) [Lipodystrophy syndrome in HIV infection]. Hautarzt 51: 159\u2013163","journal-title":"Hautarzt"},{"key":"1240_CR13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00105-005-0911-z","volume":"56","author":"Hartmann","year":"2005","unstructured":"Hartmann M, Brust J, Schuster D et al. (2005) [Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz]. Hautarzt 56: 847\u2013853","journal-title":"Hautarzt"},{"key":"1240_CR14","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1086\/339751","volume":"34","author":"Hewitt","year":"2002","unstructured":"Hewitt RG (2002) Abacavir hypersensitivity reaction. Clin Infect Dis 34: 1137\u20131142","journal-title":"Clin Infect Dis"},{"key":"1240_CR15","first-page":"823","volume":"129","author":"Hoigne","year":"1999","unstructured":"Hoigne R, Hunziker T (1999) [Maculopapular exanthema: should suspected drugs continue to be used?]. Schweiz Med Wochenschr 129: 823\u2013824","journal-title":"Schweiz Med Wochenschr"},{"key":"1240_CR16","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00002030-200404300-00019","volume":"18","author":"Izzedine","year":"2004","unstructured":"Izzedine H, Isnard-Bagnis C, Hulot JS et al. (2004) Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 18: 1074\u20131076","journal-title":"AIDS"},{"key":"1240_CR17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1055\/s-2003-39948","volume":"23","author":"Kontorinis","year":"2003","unstructured":"Kontorinis N, Dieterich DT (2003) Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 23: 173\u2013182","journal-title":"Semin Liver Dis"},{"key":"1240_CR18","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.aids.0000171419.29905.93","volume":"19","author":"Liechty","year":"2005","unstructured":"Liechty CA, Solberg P, Mwima G et al. (2005) Nevirapine-induced Stevens-Johnson syndrome in a mother and son. AIDS 19: 993\u2013994","journal-title":"AIDS"},{"key":"1240_CR19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0140-6736(02)07873-X","volume":"359","author":"Mallal","year":"2002","unstructured":"Mallal S, Nolan D, Witt C et al. (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359: 727\u2013732","journal-title":"Lancet"},{"key":"1240_CR20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00002030-200501030-00014","volume":"19","author":"Martin","year":"2005","unstructured":"Martin AM, Nolan D, James I et al. (2005) Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19: 97\u201399","journal-title":"AIDS"},{"key":"1240_CR21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7326\/0003-4819-117-6-487","volume":"117","author":"McLeod","year":"1992","unstructured":"McLeod GX, Hammer SM (1992) Zidovudine: five years later. Ann Intern Med 117: 487\u2013501","journal-title":"Ann Intern Med"},{"key":"1240_CR22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00002030-200103300-00011","volume":"15","author":"Moore","year":"2001","unstructured":"Moore RD, Keruly JC, Chaisson RE (2001) Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS 15: 617\u2013620","journal-title":"AIDS"},{"key":"1240_CR23","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0149-2918(00)80064-8","volume":"22","author":"Moyle","year":"2000","unstructured":"Moyle G (2000) Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 22: 911\u2013936","journal-title":"Clin Ther"},{"key":"1240_CR24","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00126334-200403010-00007","volume":"35","author":"Peyriere","year":"2004","unstructured":"Peyriere H, Reynes J, Rouanet I et al. (2004) Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35: 269\u2013273","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1240_CR25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00015550310002611","volume":"83","author":"Rotunda","year":"2003","unstructured":"Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM (2003) Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 83: 1\u20139","journal-title":"Acta Derm Venereol"},{"key":"1240_CR26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00126334-200211010-00001","volume":"31","author":"Schambelan","year":"2002","unstructured":"Schambelan M, Benson CA, Carr A et al. (2002) Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 31: 257\u2013275","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1240_CR27","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1086\/313826","volume":"30","author":"Sherman","year":"2000","unstructured":"Sherman DS, Fish DN (2000) Management of protease inhibitor-associated diarrhea. Clin Infect Dis 30: 908\u2013914","journal-title":"Clin Infect Dis"},{"key":"1240_CR28","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1310\/0KX0-H9VH-99EE-5D0L","volume":"7","author":"Smith","year":"2006","unstructured":"Smith DE, Jeganathan S, Ray J (2006) Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials 7: 34\u201338","journal-title":"HIV Clin Trials"},{"key":"1240_CR29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.iac.2004.03.006","volume":"24","author":"Temesgen","year":"2004","unstructured":"Temesgen Z, Beri G (2004) HIV and drug allergy. Immunol Allergy Clin North Am 24: 521\u201331","journal-title":"Immunol Allergy Clin North Am"},{"key":"1240_CR30","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","volume":"363","author":"Van","year":"2004","unstructured":"Van LF, Phanuphak P, Ruxrungtham K et al. (2004) Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 363: 1253\u20131263","journal-title":"Lancet"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1240-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-006-1240-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-006-1240-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:37:13Z","timestamp":1558582633000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-006-1240-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["1240"],"URL":"https:\/\/doi.org\/10.1007\/s00105-006-1240-6","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}